Glenmark
A new way For a new world

May 19, 2015

The Manager- Listing
National Stock Exchange of India Limited,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051.

Subject: Disclosure under Listing Agreement

Dear Sir,

This is to inform you that the Preferential Issue Committee of the Board of Directors of the Company, at its Meeting held on May 19, 2015 allotted 1,08,00,000 Equity Shares of the face value of Re. 1/- each at a price of Rs. 875 per equity share to Aranda Investments (Mauritius) Pte Ltd., on preferential basis in terms of Chapter VII of SEBI (ICDR) Regulations and the applicable sections of the Companies Act, 2013.

The above is for your information and record.

Thanking You.

Yours Faithfully,
For Glenmark Pharmaceuticals Ltd.

Sanjay Kumar Chowdhary
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099
T: 91 22 4018 9999 F: 91 22 4018 9988 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026
CIN No: L24299MH1977PLC019982 E: complianceofficer@glenmarkpharma.com